BLUEPRINT to decode the epigenetic signature written in blood
Recently, Nature Biotech published a paper about the BLUEPRINT project which aims at decoding the epigenetic signature in haematopoietic cells from healthy individuals and their malignant leukaemic counterparts. At the same time, the official project website of the BLUEPRINT project was released, with an informative film about the project. BLUEPRINT is one of the two first so-called high impact research initiatives a large-scale research projects of the EU, receiving close to 30 million euro funding from the EU. 41 leading European universities, research institutes and industry entrepreneurs will collaborate to generate at least 100 reference epigenomes and study them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. This aim feeds into the overall objective of the International Human Epigenome Consortium (IHEC). Reference epigenomes will be generated by state-of-the-art technologies from highly purified cells for a comprehensive set of epigenetic marks in accordance with quality standards set by IHEC. Nature Biotech publication: http://www.nature.com/nbt/journal/v30/n3/full/nbt.2153.html(opens in new window) Website: www.blueprint-epigenome.eu
Countries
Austria, Belgium, Bulgaria, Cyprus, Czechia, Germany, Denmark, Estonia, Greece, Spain, Finland, France, Hungary, Ireland, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, United Kingdom